Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Status:
Completed
Trial end date:
2018-12-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K
delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.